Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1.

Evid Based Complement Alternat Med · 2015 · PMC4691523 · PMID 26783407

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

This showed a significant trend towards improved survival in QYHJ group compared to either control group or gemcitabine group, with median survival time of 38.0, 32.0, and 21.0 days, respectively ( P < 0.01 compared to control group and P < 0.01 compared to gemcitabine group).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.